Pharmas Urged To Take Committed Steps Along The IDN Pathway
Integrated Delivery Networks can have a major influence on the drug classes prescribed by physicians affiliated with their network. IMS urges pharma companies to approach these increasingly important partners in health care delivery with strategies that are significantly different than those they've used in the past.
You may also be interested in...
The findings of the Cumberlege Review into how safety issues for three medical product groups were handled will shape debate on the UK’s new devices legislation, now going through parliament. The MHRA’s devices regulatory activity also comes in for scrutiny.
Top of the agenda for the medtech industry globally is when the “new normal” will return. In the UK, the expectations are that post-COVID-19 health care activity will increase gradually, but it is possible that the National Health Service will not reach its pre-coronavirus capacities until late in 2021, “if at all.”
Residual resistance to digital health care solutions in the UK NHS disappeared “almost overnight” when COVID-19 compelled the rapid adoption of new tools to meet the surge in demand and cope with supply challenges.